.Pharmacolibrary.Drugs.ATC.J.J05AR22 .Pharmacolibrary.Drugs.ATC.J.J05AR22| name: | EmtricitabineTenofovirAlafenamideDarunavirAndCobicistat | |
| ATC code: | J05AR22 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 1.1 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
Emtricitabine, tenofovir alafenamide, darunavir, and cobicistat is a fixed-dose combination antiretroviral medication used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents. The combination includes two nucleoside reverse transcriptase inhibitors (emtricitabine, tenofovir alafenamide), a protease inhibitor (darunavir), and a pharmacokinetic enhancer (cobicistat). The medicine is approved for use, commonly marketed in fixed-dose combinations, such as Symtuza.
Estimated pharmacokinetic parameters based on available published information for each constituent in healthy adult subjects after oral administration in the fixed-dose combination. Specific published pharmacokinetic models for the combination product are not available.